Quantum Genomics appoints Sarah Merlen Boulenger as Head of Regulatory Affairs
Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC)
a biopharmaceutical company specializing in the development of a new class of drugs that act directly on the brain to treat difficult to treat/resistant hypertension and heart failure, strengthens its team with the appointment of Sarah Merlen Boulenger as Chief Regulatory Affairs.
Sarah Merlen Boulenger joins Quantum Genomics to prepare the registration dossier for firibastat in the treatment of difficult to treat and resistant hypertension and to implement the operational strategy for submitting marketing applications, primarily in the United States and in Europe and then in the various territories targeted by the company’s partner pharmaceutical laboratories.
Holder of a doctorate in pharmacy from the University of Lille, a Master 1 in Modern Methods of Drug Discovery and Development and a Master 2 in Drug Regulation in the European Union, Sarah Merlen Boulenger has occupied various positions within the Regulatory Affairs departments of Sanofi, Ethypharm in France and the United States.
”
I am delighted to join Quantum Genomics and bring to the team my experience in Regulatory Affairs to support the finalization of the clinical development of firibastat in difficult to treat hypertension and in heart failure, and to prepare its registration, in first place with the Food and Drug Administration
said Sarah Merlen Boulenger, Head of Regulatory Affairs at Quantum Genomics.
”
The Quantum Genomics team and I are very happy to welcome Sarah. After the appointment of Stéphane Cohen as Director of Global Operations, his recruitment strengthens our ability to deploy an effective firibastat registration strategy worldwide. Because this is of course an essential and major step for Quantum Genomics, we wanted to build a larger team of complementary professionals to successfully prepare the launch of this drug which aims to offer a new therapeutic option to patients. hypertensives whose blood pressure is not sufficiently controlled by existing treatments
commented Jean-Philippe Milon, CEO of Quantum Genomics.
About Quantum Genomics
Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular drugs, based on the mechanism of inhibition of brain Aminopeptidase A (Brain Aminopeptidase A Inhibition or BAPAI). The only company in the world to pursue this innovative approach directly targeting the brain, it relies on more than twenty years of research from the University of Paris-Descartes and the INSERM/CNRS laboratory directed by Dr. Catherine Llorens-Cortès at France secondary school. Quantum Genomics thus aims to develop innovative treatments for complicated or even resistant arterial hypertension (about 30% of patients are poorly controlled or fail treatment), and heart failure (one out of two diagnosed patients dies within five years).
Based in Paris, the company is listed on the Euronext Growth market in Paris (FR0011648971 – ALQGC) and registered on the American market OTCQX (symbol: QNNTF).
More information on www.quantum-genomics.com, our Twitter and Linkedin accounts
contacts
|
Quantum Genomics | |
|
Communication building (EUROPE) | |
Financial communication and media | |
|
LifeSci (US) | |
Mike Tattory |
This post has the “? Actusnews SECURITY MASTER” service.
– SECURITY MASTER Key:
lW5tZMiXZpvKx5+bap1nZpeWaW5klJTGlmbHyGhtlsmVnG6SmZuVapmZZnBlmWlt
– To check this key:
https://www.security-master-key.com.
Regulated information:
Inside information:
– Other press releases
Full and original press release in PDF format:
https://www.actusnews.com/news/74447-cp-sarah-merlen_fr.pdf
© Copyright Actusnews Wire
Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com